Evidence map›Paper›PMID 38118006›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

CAPTURA Regional Workshop Proceedings (28-30 June 2022, Virtual).

Hea Sun Joh, Brooke Dolabella, Emmanuel Early, John Stelling, Gabriella Ak, Madan Kumar Upadhyaya, Aninda Rahman, Pem Chuki, William R MacWright, Pascale Ondoa and 9 more

Abstract readConference Proceedings
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hea Sun JohInternational Vaccine Institute, Seoul, Republic of Korea.ORCID 0000-0002-2107-0919
Brooke DolabellaPublic Health Surveillance Group, LLC, Princeton, New Jersey, USA.
Emmanuel EarlyInternational Vaccine Institute, Seoul, Republic of Korea.
John StellingBrigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Gabriella AkPort Moresby General Hospital, Port Moresby, Papua New Guinea.
Madan Kumar UpadhyayaMinistry of Health and Population, Kathmandu, Nepal.
Aninda RahmanCommunicable Disease Control, Directorate General of Health Services, Ministry of Health and Family Welfare, Dhaka, Bangladesh.
Pem ChukiJigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan.
William R MacWrightPublic Health Surveillance Group, LLC, Princeton, New Jersey, USA.
Pascale OndoaAfrican Society for Laboratory Medicine, Addis Ababa, Ethiopia.
Satyajit SarkarInternational Vaccine Institute, Seoul, Republic of Korea.
Catrin MooreInstitute of Infection and Immunity at St George's, University of London, London, United Kingdom.
Marianne HolmInternational Vaccine Institute, Seoul, Republic of Korea.
Toby LeslieFleming Fund Management Agent, Mott MacDonald, London, United Kingdom.
Raphaël M ZellwegerInternational Vaccine Institute, Seoul, Republic of Korea.
Giyoung PaingInternational Vaccine Institute, Seoul, Republic of Korea.
Soo Young KwonInternational Vaccine Institute, Seoul, Republic of Korea.
Florian MarksInternational Vaccine Institute, Seoul, Republic of Korea.
Nimesh PoudyalInternational Vaccine Institute, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In response to the global threat of antimicrobial resistance (AMR), the Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA) project worked with microbiology laboratories, pharmacies, and local governments in South Asia and Southeast Asia to expand the volume of historical and current data available on AMR and antimicrobial use and to identify gaps in data and areas for quality improvement. When the CAPTURA project completed its country-level engagement in the first half of 2022, the consortium brought together local, regional, and global AMR stakeholders for a virtual regional workshop to review data outputs from the project and share strategies to inform national and regional efforts to combat AMR. This paper summarizes the main topics presented in the workshop held from 28 to 30 June 2022. As such, it highlights lessons learned from the project and strategies to fight AMR. Although CAPTURA has been invaluable to countries and information from the project is already being used, barriers concerning data quality and sharing remain. Regional-level initiatives should continue to build on the momentum gained from the CAPTURA project in supporting national-level surveillance and data quality improvements to inform critical decisions around planning, policies, and clinical care. Project findings have highlighted that issues with antimicrobial resistance and use are wide ranging across countries. Going forward, building on the current foundations and tailoring approaches to meet local needs and capacities will be fundamental in combatting AMR.

Indexed as

Anti-Infective AgentsData AccuracyAnti-Bacterial AgentsAsiaDrug Resistance, BacterialHumansLaboratoriesPolicyAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Resistance (AMR)Fleming Fund Regional GrantRegional WorkshopSouth AsiaSoutheast Asia

Identifiers

PMID38118006
PMCPMC10732551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.